Human Immunology News 5.10 March 14, 2017 | |
| |
TOP STORYDifferential Role of Pannexin-1/ATP/P2X7 Axis in IL-1β Release by Human Monocytes Investigators found that pro-IL-1β and mature IL-1β release from human monocytes is stimulated by the TLR2 agonists Pam3CSK4 or FSL-1 as well as the TLR4 agonist LPS in the absence of additional ATP. [FASEB J] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Cytochrome P450s in Human Immune Cells Regulate IL-22 and c-Kit via an AHR Feedback Loop Scientists studied the interdependence of cytochrome P4501 enzymes (CYP1) and aryl hydrocarbon receptor (AHR) in human primary immune cells using pharmacological methods. CYP1 inhibition increased the expression levels of the stem cell factor receptor (c-Kit) and interleukin (IL)-22 but decreased IL-17. [Sci Rep] Full Article Eight color fluorescence activated cell sorting panels were designed to study human natural killer (NK) cell phenotype and function within peripheral blood mononuclear cells. The panels were designed around fixed backbone markers and channels, covering antigens for non-NK lineage exclusion and NK cell selection, complemented with variable drop-in markers/channels to study NK cell phenotype or NK cell function and activation. [Sci Rep] Full Article Distinct Expression and Function of FcεRII in Human B Cells and Monocytes Researchers evaluated the expression of FcεRII on human blood cells and found that it was primarily expressed on monocytes and B cells. Although IL-4 promoted expression of the FcεRIIb isoform on B cells and monocytes, the expression of the FcεRIIa isoform was not dependent on IL-4. [J Immunol] Abstract Researchers dissected the impact of innate immune sensing by pathogen recognition receptors on dendritic cell (DC) maturation, HIV infection and on the quality of HIV-specific cytotoxic T-cell (CTL) activation. Remarkably, ligand-driven triggering of TLR-3, -4, NOD2 and DC-SIGN, despite reducing viral replication, markedly increased the capacity of infected DCs to stimulate HIV-specific CTLs. [Eur J Immunol] Abstract Investigators showed that suppression of CD25 expression by tert-butylhydroquinone (tBHQ) is partially dependent on nuclear factor erythroid 2-related factor 2 (Nrf2), whereas inhibition of IL-2 secretion is largely Nrf2-independent. Interestingly, tBHQ inhibited NFκB activation in a Nrf2-independent manner. [J Pharmacol Exp Ther] Abstract Scientists describe an approach to quantify cytotoxic T-cells (CTL)-mediated cytotoxicity using imaging flow cytometry. Using activated primary human cytotoxic T-cells as CTLs and P815 as target cells, they showed that both the evaluation of target cell death and the biology of CTLs can be evaluated in parallel. [J Cell Biochem] Abstract To efficiently gauge both the innate and the adaptive immune response, two novel 15-color antibody panels to identify key myeloid and T cell subsets and their functional potential were established. This approach was used to compare cellular immune profiles in fresh whole blood and in matched cryopreserved peripheral blood mononuclear cells. [Cytometry A] Abstract Dynamin2 Controls Rap1 Activation and Integrin Clustering in Human T Lymphocyte Adhesion The authors report that the large GTPase dynamin2, which is generally considered to have a key role in endocytosis and membrane remodeling, is an essential regulator of integrin-dependent human T lymphocyte adhesion and migration. [PLoS One] Full Article Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSTranscription Factor T-Bet Orchestrates Lineage Development and Function in the Immune System T-bet broadly regulates transcriptional programs in response to type 1 inflammatory signals and mediates the coordinated differentiation, function, migration and survival of effector and memory lymphocyte subsets in the affected tissue. [Trends Immunol] Abstract Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSVedantra Pharmaceuticals, Inc. announced a joint collaboration to explore cancer vaccine research with Neon Therapeutics. The two companies will contribute their respective expertise non-exclusively to explore the potential benefits of combining Vedantra’s cutting edge albumin-binding, lymph node targeting amphiphile technology with Neon’s innovative capabilities in neoantigen vaccine research. [Vedantra Pharmaceuticals, Inc. (Business Wire, Inc.)] Press Release Servier and Cellectis announced that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S. with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia. [Cellectis, Inc.] Press Release Celyad Obtains FDA Approval to Initiate the NKR-2 CAR T Cells THINK Trial in the USA Celyad announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological malignancies. [Celyad] Press Release | |
| |
POLICY NEWSU.K. Scientists Prepare for Impending Break with European Union For months after the United Kingdom (U.K.) voted last June to leave the European Union (EU), many British scientists clung to hopes of a “soft Brexit,” which would not cut them off from EU funding and collaborators. But Prime Minister Theresa May, who is expected to trigger the two-year process of exiting the European Union, has signaled the break will be sharp. U.K. researchers are now facing up to the prospect that they won’t be able to apply for EU funding or easily recruit students and colleagues from the rest of Europe. [ScienceInsider] Editorial Canada’s New Genetic Privacy Law Is Causing Huge Headaches for Justin Trudeau A vote in Canada’s Parliament to approve a genetic privacy bill is creating a self-inflicted political headache for Prime Minister Justin Trudeau’s Liberal government—and could result in a relatively rare and unusual court case. [ScienceInsider] Editorial Physician with Drug-Industry Ties Is Trump’s FDA Pick President Donald Trump has nominated Scott Gottlieb — a conservative pundit, physician and venture capitalist — to head the US Food and Drug Administration (FDA). [Nature News] Editorial
| |
EVENTSNEW Keystone Symposium: Integrating Metabolism and Immunity Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Stromal Tissues Imprinting of Immune Cell Function (AstraZeneca) NEW Postdoctoral Fellow – Immune-Oncology (Johnson and Johnson) Research Technologist – Cell Separation & Immunology (STEMCELL Technologies, Inc.) Postdoctoral Researcher – Development of Immune System (Lund University) Research Investigator – Immuno-Oncology (Bristol-Meyers Squibb) Postdoctoral Fellow – Immune Regulation and Human Diseases (The Wistar Institute) Bioinformatician – Immunology (KOTAI Biotechnologies, Inc.) Scientist – Immunology (Moderna Therapeutics) Research Scientist – CAR-T Start-Up (Leucid Bio) Postdoctoral Fellow – Immunology (The University of Texas Medical School at Houston) Postdoctoral Fellow – Molecular Immunology (University of California San Diego School of Medicine) Assistant Associate – Cancer Immunology (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|